TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2023

Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults.

Chen Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.